Medical devices — US PTAB Patent Cases
522 decisions indexed
Page 6 of 18 · 522 total
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and Apple have filed an IPR petition challenging Omni MedSci’s ’533 patent covering wearable optical health monitors. The petition asserts obviousness over Lisogurski, Carlson, and Mannheimer references and asks the Board to institute the review and cancel the claims.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition seeking to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent. The petition argues the claims are obvious over a combination of five prior‑art references and requests that the Board institute the trial.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple seeks to invalidate Omni MedSci’s wearable health‑monitor patent, arguing that all challenged claims are obvious over prior art. The petition requests the PTAB to institute an IPR and cancel the claims.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed on 12 of the 23 challenged claims of Omni MedSci’s wearable physiological monitoring patent, finding them obvious over multiple prior‑art references. The remaining claims were left unpatentable pending further proof.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Apple’s wearable physiological measurement claims were obvious over prior‑art pulse‑oximetry references, rendering all challenged claims unpatentable. The decision relied on Lisogurski, Carlson, and Mannheimer teachings.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR resulted in the Board finding all six challenged claims of Omni MedSci’s ’299 patent unpatentable as obvious over a combination of prior‑art references covering wearable optical sensing.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision in IPR2021‑00453, finding claims 1,2,7 and 15‑23 of Omni MedSci’s wearable pulse‑oximeter patent unpatentable over prior art, while leaving the remaining claims intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable physiological measurement patent resulted in all challenged claims being held unpatentable. The Board found the claims obvious over Lisogurski, Carlson, and Mannheimer under §103(a).
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s inter‑partes review of Omni MedSci’s ’533 patent resulted in the PTAB finding all challenged claims unpatentable for obviousness over Lisogurski, Carlson, and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple won a PTAB IPR against Omni MedSci, finding 12 of the 23 challenged claims of the 10,517,484 B2 wearable health‑monitoring patent unpatentable, while the remaining claims survived.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable health‑monitoring patent resulted in the Board finding all challenged claims unpatentable as obvious over a combination of prior‑art references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) secured a Final Written Decision finding claims 1,2,7,15‑23 of Omni MedSci’s wearable health‑monitoring patent unpatentable as obvious over prior‑art. The Board affirmed the petitioner's obviousness arguments while leaving claims 3‑6 and 8‑14 intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s petition succeeded; the PTAB held all challenged claims of Omni MedSci’s wearable physiological measurement patent unpatentable as obvious over Lisogurski, Carlson, and Mannheimer references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision on remand, holding that all 23 claims of Omni MedSci’s wearable pulse‑oximeter patent are unpatentable. The Board relied on an obviousness analysis over a combination of prior‑art references and affirmed the claim construction of “identify an object.”
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci, finding claims 7 and 10‑14 of the ’299 patent unpatentable for obviousness over Lisogurski, Carlson, Mannheimer, and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Samsung’s challenge to Omni MedSci’s wearable physiological monitoring patent succeeded on 12 of the 23 claims, finding them obvious over prior‑art references such as Lisogurski, Carlson, Tran, Isaacson and Valencell‑093. The remaining claims were not shown unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s ‘533 patent resulted in all challenged claims being found unpatentable. The Board held that the claims were obvious over prior‑art references Lisogurski, Carlson, and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s wearable physiological‑monitoring patent was declared entirely unpatentable after Samsung’s PTAB challenge, with the Board finding the claims obvious over a combination of prior‑art references covering optical sensors, pulse‑rate modulation, spaced emitters, and reflective surfaces.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable health monitoring patent concluded with the Board finding all 23 claims unpatentable for obviousness. The decision affirmed the claim construction of “identify an object” and rejected the need for further briefing.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple, on behalf of Samsung, filed an IPR petition challenging Omni MedSci’s ’533 patent covering wearable optical health monitors. The petition asserts that the claims are obvious over prior art (Lisogurski, Carlson, Mannheimer) and seeks institution of the review.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in IPR2020‑00175, with the PTAB finding all six challenged claims of the ’299 patent unpatentable as obvious over Lisogurski, Carlson, Mannheimer and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci’s wearable health‑monitoring patent, finding 12 of the 23 claims unpatentable while the remaining claims survived.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition challenging Omni MedSci’s ’533 wearable health‑monitoring patent, arguing that all asserted claims are obvious over prior‑art references Lisogurski, Carlson and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung (on behalf of Apple) petitions the PTAB to invalidate Omni MedSci’s 9,651,533 patent covering wearable optical health monitors. The petition asserts obviousness over Lisogurski, Carlson, and Mannheimer references and requests that the trial be instituted.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition seeking to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent. The petition relies on a combination of five prior‑art references to argue obviousness of all 23 claims. The case is pending institution.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed in an IPR against Omni MedSci’s 9,651,533 patent, with the PTAB finding all challenged claims unpatentable as obvious over Lisogurski, Carlson, and Mannheimer. The decision hinges on pulse‑rate and signal‑to‑noise teachings in the prior art.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and co‑petitioners have filed a PGR seeking to invalidate claim 7 of Omni MedSci’s 12,193,790 patent, arguing obviousness over Lisogurski and Carlson and invoking collateral estoppel from earlier IPRs.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and co‑petitioners have filed an IPR petition challenging Omni MedSci’s wearable health‑monitoring patent, asserting obviousness over multiple prior‑art references and invoking collateral estoppel from earlier IPRs.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and co‑petitioners seek an IPR of Omni MedSci’s ’455 wearable health‑monitoring patent, arguing the claims are obvious over prior art and that earlier IPR findings estop re‑litigation. They request the Board institute the proceeding.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and co‑petitioners have filed an IPR petition against Omni MedSci’s U.S. Patent 12,193,790, asserting that claim 7 is obvious over Lisogurski and Carlson references and should be barred by collateral estoppel.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.